Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 14/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CCNH | P51946 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521539 | 0.87 | IKBKB (0.76) | IKBKBMAPK8MAPK10CDK2CDK4 | |
| SCHEMBL6027228 | 0.83 | IKBKB (0.66) | IKBKBMAPK8MAPK10CDK2 | |
| SCHEMBL3520747 | 0.81 | IKBKB (0.52) | IKBKBCDK2CDK4CCNT1CDK1 | |
| SCHEMBL3520839 | 0.81 | CDK2 (0.52) | IKBKBMAPK8CDK2CDK4CCNT1 | |
| SCHEMBL4903401 | 0.81 | IKBKB (0.67) | IKBKBMAPK8MAPK10CCNT1CDK9 | |
| SCHEMBL3516413 | 0.77 | IKBKB (0.58) | IKBKBMAPK8MAPK10CAMK2D | |
| SCHEMBL3521365 | 0.75 | GSK3B (0.57) | IKBKBMAPK8CDK2CCNT1CDK1 | |
| SCHEMBL7470313 | 0.75 | ABL1 (0.58) | IKBKBMAPK8MAPK10CDK1CCNB1 | |
| SCHEMBL3519092 | 0.74 | IKBKB (0.69) | IKBKBMAPK8MAPK10CDK2CCNT1 | |
| SCHEMBL3518431 | 0.74 | IKBKB (1.00) | IKBKBMAPK8MAPK10CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | claimed |
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | IKBKB 1593/4885MAPK8 205/4885MAPK10 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.